Skip to main content

Main menu

  • Pipeline
    • Clinical
    • Discovery
    • Compounds
    • Regimens
    • Drug Targets
    • Developers
    • Trial Sites
    • Trials
  • News
  • Meetings
  • Members
    • Our Members
    • Core Group
  • About
  • Join Us
Drug Target

DPRE1 Noncovalent Inhibitors

Compound Associations
Phase 2. Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
Phase 2. Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
Phase 2b/c. 4-month Regimen of OPC-167832, Delamanid and Bedaquiline for DS Pulmonary TB
Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
TBA-7371
Description
  Would you like to receive updates from the WGND? Join our mailing list:
Interests

About Us

Part of Stop TB Partnership, we are a network of committed individuals devoted to accelerating the development of effective, affordable new therapies for TB.

Visit the Stop TB Partnership
Read about The Global Plan to End TB

Navigate

  • Clinical Pipeline
  • Discovery
  • Developers
  • Trials
  • Trial Sites
  • News
  • Meetings
  • Core Group
  • Members
  • About

Contact

The Working Group for New TB Drugs

80 Pine Street, Fl 20th
New York, NY

Contact Us

Follow Us

©2016 Working Group on New TB Drugs. All Rights Reserved. Terms of Reference Site by Darby Communications